Last updated:  11/07/2018 19:48:41
A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and midazolam regimen versus a morphine and midazolam regimen in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
Clinicaltrials.gov ID 
Not applicable
EudraCT ID 
Not applicable
EU CT Number 
Not applicable
Trial status 
                  Study complete
                
Study complete
Trial overview
Official title: A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and midazolam regimen versus a morphine and midazolam regimen in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
Trial description: A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and midazolam regimen versus a morphine and midazolam regimen in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes: 
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Kessler P, Chinachoti T, Van Deer Berg P et al. Remifentanil vs. morphine for the provision of optimal sedation in ICU patients. Intensive Care Medicine 2001; 27: Supplement 2 S239. A406.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-25-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website